A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohn’s Disease May 5, 2022 By Jesse Bufkin
A Pivotal Study of SGN-35 in Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) May 5, 2022 By Jesse Bufkin
A Pilot Study of the Use of Intrapartum Intraveneous Acyclovir Followed by Oral Acyclovir to the Neonate To Prevent Neonatal Herpes Among HSV-2 Seropositive Women with HSV Detected in Genital Secretins at the Time of Labor May 5, 2022 By Jesse Bufkin
Multi-Parametric MRI for Early Assessment of Treatment Response in Breast Tumors May 5, 2022 By Jesse Bufkin
A Prospective, Randomized, Controlled Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema May 5, 2022 By Jesse Bufkin
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma May 5, 2022 By Jesse Bufkin
A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative Colitis May 5, 2022 By Jesse Bufkin
A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Crohn’s Disease May 5, 2022 By Jesse Bufkin
A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone May 5, 2022 By Jesse Bufkin
